To the full analysis
Merit Medical Systems stock: growth
MMSIMerit Medical Systems reported $1.51B in revenue for fiscal 2025, up 11.7% on the prior year, up 9.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
11.5%
per year from 2006 to 2025, per share 8.3%
Earnings (Annual rate)
13.1%
per year from 2006 to 2025, per share 9.9%
Free cash flow (Annual rate)
23.1%
per year from 2006 to 2025, per share 19.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 9.5% | 10.8% | 11.5% |
| Revenue per share | 8.0% | 7.6% | 8.3% |
| Earnings | no data | 18.4% | 13.1% |
| Earnings per share | no data | 14.9% | 9.9% |
| Free cash flow | 12.9% | 29.1% | 23.1% |
| Free cash flow per share | 11.4% | 25.3% | 19.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $190.67M | $12.3M | $4.11M |
| 2007 | $207.77M | $15.59M | $15.38M |
| 2008 | $227.14M | $20.73M | $13.06M |
| 2009 | $257.46M | $22.53M | $10.4M |
| 2010 | $296.76M | $12.46M | $10.03M |
| 2011 | $359.45M | $23.04M | −$27.26M |
| 2012 | $394.29M | $19.71M | −$19.17M |
| 2013 | $449.05M | $16.57M | −$9.75M |
| 2014 | $509.69M | $22.97M | $17.43M |
| 2015 | $542.15M | $23.8M | $16.54M |
| 2016 | $603.84M | $20.12M | $18.55M |
| 2017 | $727.85M | $27.52M | $21.53M |
| 2018 | $882.75M | $42.02M | $20.2M |
| 2019 | $994.85M | $5.45M | −$3.68M |
| 2020 | $963.88M | −$9.84M | $115.99M |
| 2021 | $1.07B | $48.45M | $119.29M |
| 2022 | $1.15B | $74.52M | $69.26M |
| 2023 | $1.26B | $94.41M | $108.45M |
| 2024 | $1.36B | $120.36M | $182.76M |
| 2025 | $1.51B | $128.49M | $212.54M |
Revenue by segment
How Merit Medical Systems, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Cardiovascular95%
- Endoscopy5%
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $580.25M | $700.61M | $849.48M | $960.98M | $934.2M | $1.04B | $1.12B | $1.22B | $1.3B | $1.44B | 95.3% |
| Endoscopy | $23.59M | $27.24M | $33.28M | $33.87M | $29.67M | $31.52M | $32.76M | $36.81M | $54.77M | $72.86M | 4.8% |
| Total revenue | $603.84M | $727.85M | $882.75M | $994.85M | $963.88M | $1.07B | $1.15B | $1.26B | $1.36B | $1.51B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 28 Feb 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.